Xinxiang OriginBio Biotechnology Co., Ltd., established in April 2020 and located in Fengquan District, Xinxiang City, Henan Province, is a high-tech enterprise specializing in the field of in vitro diagnostics (IVD). The company focuses on three core business areas: rapid pathogen detection, precision medication guidance for chronic diseases through genetic testing, and early cancer screening and companion diagnostics. These areas are closely aligned with the national strategy of integrating prevention and treatment, providing scientific decision-making support for clinical diagnosis and treatment.

In terms of industrial layout, the company has taken the lead in establishing the first intelligent shared GMP workshop in Henan Province, building a large-scale production system that meets international standards. This achieves seamless integration from R&D to mass production, laying a solid foundation for the independent mass production of core products. As a professional medical device CDMO+CRO shared platform, the company offers comprehensive one-stop services from reagent development, clinical collaboration, registration and certification, production, to market launch. It precisely addresses the pain points faced by small and medium-sized enterprises and research institutions during the industrialization process, such as high costs, long cycles, compliance difficulties, and regulatory challenges, effectively shortening the cycle of technology commercialization.

The company’s business closely aligns with the “Healthy China” strategy. Its rapid pathogen detection service enhances emergency testing capabilities at the grassroots level, its precision medication guidance for chronic diseases fits well with the needs of hierarchical diagnosis and treatment, and its early cancer screening service actively responds to cancer prevention and control policies. Through the synergistic operation of dual platforms, the company not only achieves steady growth but also empowers innovative entities throughout the industrial chain, promoting the standardization and autonomy of the medical device industry.

Looking ahead, the company will continue to drive forward with technological innovation at its core, improving the service capabilities of its shared platform and optimizing the entire industrial ecosystem. It aims to provide efficient and compliant industrial solutions for the healthcare industry, facilitate the market entry of high-quality medical devices, and contribute to enhancing the competitiveness of China’s healthcare industry.